PD 98059

  • CAT Number: I002194
  • CAS Number: 167869-21-8
  • Molecular Formula: C16H13NO3
  • Molecular Weight: 267.28
  • Purity: 98%
Inquiry Now

PD 98059(CAT: I002194) is a potent and selective inhibitor of the MAP kinase kinase (MEK) signaling pathway. MEK is a protein kinase that plays a critical role in the regulation of cell growth and proliferation, as well as differentiation and survival. PD 98059 works by specifically blocking the activity of MEK1 and MEK2, which are important downstream targets of the Ras-Raf-MEK-ERK signaling pathway. PD 98059 has been widely used in preclinical studies to investigate the role of the MEK pathway in various biological processes, including cancer development and progression, inflammation, and neuronal plasticity. PD 98059 has also been used as a tool compound for the development of other MEK inhibitors with improved potency and selectivity. However, PD 98059 has limited use in clinical studies due to its poor pharmacokinetic properties and potential for off-target effects.

Catalog Number I002194
CAS Number 167869-21-8
Molecular Formula


Purity 98
Target MEK1/2
Solubility DMSO: ≤ 16 mg/mL, H2O: < 0.01 mg/mL
Storage Store at -20°C
IC50 2 uM
InChI InChI=1S/C16H13NO3/c1-19-14-8-4-6-11(16(14)17)15-9-12(18)10-5-2-3-7-13(10)20-15/h2-9H,17H2,1H3

1. Clin Exp Pharmacol Physiol. 2003 Apr;30(4):273-7.<br />
The p42/44mitogen-activated protein kinase inhibitor PD 98059, but not U 0126, increases a K+ current in cardiomyocytes.<br />
Aimond F(1), Fauconnier J, Donadille D, Vassort G.<br />
Author information:<br />
(1)INSERM U-390, Physiopathologie Cardiovasculaire, IFR No. 3, Montpellier, France.<br />
1. The effects of the mitogen-activated protein kinase (MAPK) inhibitors PD 98059 and U 0126, useful tools to investigate MAPK involvement in intracellular signal transduction pathways, were assessed on cardiomyocytes. 2. In rat freshly isolated ventricular myocytes, under current-clamp conditions, PD 98059 (40 micro mol/L) shortened the action potential. Under whole-cell patch-clamp, this compound slowly induced a fast activating sustained outward K+ current that was sensitive to 1 mmol/L Ba2+, 100 micro mol/L Gd3+, 3 mmol/L 4-aminopyridine and 100 micro mol/L tetracain. The PD 98059-induced current was prevented by 40 micro mol/L AACOCF3, a cytosolic phospholipase A2 inhibitor. 3. U 0126 (1 micro mol/L), a recently developed highly potent p42/44 MAPK inhibitor, did not alter K+ currents. 4. PD 98059, but not U 0126, increased arachidonic acid content, probably as a consequence of its reported cyclo-oxygenase inhibitory effect. 5. These observations indicate that PD 98059 activates a TREK-1 like current. Thus, this MAPK inhibitor has to be used with caution because alterations in cell metabolism can be secondary to changes in electrophysiological behaviour.<br />
2. FEBS Lett. 1998 Sep 4;434(3):241-4.<br />
Pervanadate-triggered MAP kinase activation and cell proliferation are not sensitive to PD 98059. Evidence for stimulus-dependent differential PD 98059 inhibition mechanism.<br />
Krady MM(1), Malviya AN, Dupont JL.<br />
Author information:<br />
(1)Laboratoire de Neurobiologie Mol&eacute;culaire des Interactions Cellulaires, CNRS UPR 416, Strasbourg, France.<br />
A tight and stable complex with corresponding protein kinases and phosphatases establishes coupling between activators and inactivators. One such example is emerging from the studies of the Ras-dependent MAP kinase cascade signaling pathway. Pervanadate, a potent inhibitor of protein tyrosine phosphatase, stimulates MAP kinase and elicits cell proliferation in cultured mouse fibroblasts which is insensitive to PD 98059, the major inhibitor of upstream MEK, whereas serum- or TPA-triggered proliferation is sensitive to PD 98059. It is suggested that imbalanced coordination between protein kinase and protein phosphatase determines the cellular responses such as cell proliferation. The PD 98059-insensitive cell proliferation upon protein tyrosine phosphatase inhibition is attributed to a MEK bypass pathway.<br />
3. Exp Cell Res. 1998 May 25;241(1):12-22.<br />
PD 98059 prevents establishment of the spindle assembly checkpoint and inhibits the G2-M transition in meiotic but not mitotic cell cycles in Xenopus.<br />
Cross DA(1), Smythe C.<br />
Author information:<br />
(1)Department of Biochemistry, The University, Dundee, United Kingdom.<br />
Most chemotherapeutic agents block DNA replication, damage DNA, or interfere with chromosome segregation. The existence of checkpoints, which monitor these events, indicates that mechanisms exist to avoid death when essential cellular events are inhibited. A molecular understanding of cellular checkpoints should therefore provide opportunities for the development of inhibitors of checkpoint controls which may increase the potency of chemotherapeutic drugs by inducing catastrophic cell cycle progression. The molecular dissection of cell cycle arrest points is facilitated in the Xenopus egg/oocyte system, in which cell-free systems retain both S/M and spindle assembly checkpoints. Members of the MAP kinase family have been shown to play a role in the induction of G2 to M transition during oocyte maturation and have been implicated in the maintenance of either cytostatic factor- or spindle assembly checkpoint-induced M-phase arrest. Here, we have examined the effects of the inhibitor of MAP kinase kinase activation, PD 98059, on cell cycle progression in Xenopus oocytes and in cell-free extracts. This inhibitor is highly specific for the kinase which activates the classical p42/p44 MAP kinase, having no effect on upstream activators of stress-activated protein kinases. We have found that PD 98059 inhibits oocyte maturation, consistent with a role for p42 MAP kinase as a rate-limiting component in the induction of meiosis, but had no effect on the timing of G2-M transition in cell-free extracts indicating that, unlike meiosis, p42 MAP kinase activation is not limiting for normal mitotic M phase entry. However, we found that cytostatic factor-induced metaphase arrest, as well as the spindle assembly checkpoint, were both abolished in the presence of the drug. These results demonstrate that p42 MAP kinase, and not some other member of the MAP kinase family, is responsible for both CSF- and checkpoint-induced metaphase arrest and suggest that PD 98059 and similar agents may have considerable therapeutic potential for the potentiation of chemotherapeutic regimes.<br />

Request a Quote

Contact Us at MuseChem

We are committed to providing you with reliable, cost-effective solutions for your chemical needs, while ensuring your safety and comfort. Our team of experts is always available to answer your questions and help you navigate the complexities of the chemical industry.

Whether you're looking for a specific product or need help with a custom synthesis project, we're here to help you discover a new world of chemical possibilities. Contact us today to learn more about how we can assist you with all of your chemical needs.

Our goal is to make the process of ordering chemicals as seamless and hassle-free as possible. Let us know how we can assist you, and we'll get back to you as soon as possible. We look forward to hearing from you!